Physician profile
Robert J Berkompas
NPI 1174560312
$832.85
in general payments reported to CMS, 2019-2025
16 companies · $13.93 in 2025
The $13.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $98.76 · 2021: $16.22 · 2025: $13.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $206.88 | 2019-2020 | |
| Amgen INC. | $144.41 | 2019-2020 | |
| Pfizer INC. | $120.17 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.00 | 2019 | |
| Glaxosmithkline, LLC. | $54.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.35 | 2019 | |
| Allergan, INC. | $32.68 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.07 | 2019 | |
| Merck Sharp & Dohme LLC | $29.88 | 2019 | |
| Astellas Pharma US INC | $24.40 | 2019 | |
| Gilead Sciences, INC. | $18.62 | 2019 | |
| Dexcom, INC. | $16.22 | 2021 | |
| Abbott Laboratories | $15.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.49 | 2019 | |
| Boston Scientific Corporation | $13.93 | 2025 | Farapulse |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Berkompas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.